Charles Schwab
TCRT icon

Charles Schwab’s Alaunos Therapeutics TCRT Stock Holding History

Charles Schwab’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-735
Closed -$7.8K – 3516
2023
Q4 		$7.8K Hold
735
– – ﹤0.01% 3532
2023
Q3 		$14.5K Hold
735
– – ﹤0.01% 3535
2023
Q2 		$56.3K Buy
+735
New +$59.5K ﹤0.01% 3408
2023
Q1 		– Sell
-553
Closed -$53.9K – 3590
2022
Q4 		$53.9K Hold
553
– – ﹤0.01% 3342
2022
Q3 		$143K Hold
553
– – ﹤0.01% 3197
2022
Q2 		$103K Sell
553
-3,051
-85% -$292K ﹤0.01% 3287
2022
Q1 		$353K Hold
3,604
– – ﹤0.01% 3175
2021
Q4 		$590K Buy
3,604
+117
+3% +$25.7K ﹤0.01% 3094
2021
Q3 		$952K Sell
3,487
-6,372
-65% -$1.95M ﹤0.01% 2893
2021
Q2 		$3.9M Buy
9,859
+67
+0.7% +$31.3K ﹤0.01% 2468
2021
Q1 		$5.29M Buy
9,792
+331
+3% +$206K ﹤0.01% 2278
2020
Q4 		$3.58M Buy
9,461
+181
+2% +$72K ﹤0.01% 2379
2020
Q3 		$3.51M Buy
9,280
+418
+5% +$185K ﹤0.01% 2246
2020
Q2 		$4.36M Buy
8,862
+1,018
+13% +$454K ﹤0.01% 2090
2020
Q1 		$2.88M Buy
7,844
+1,174
+18% +$608K ﹤0.01% 2107
2019
Q4 		$4.72M Buy
6,670
+157
+2% +$108K ﹤0.01% 2046
2019
Q3 		$4.18M Buy
6,513
+522
+9% +$414K ﹤0.01% 2058
2019
Q2 		$5.24M Buy
5,991
+425
+8% +$292K ﹤0.01% 1951
2019
Q1 		$3.21M Buy
5,566
+606
+12% +$253K ﹤0.01% 2188
2018
Q4 		$1.39M Buy
4,960
+438
+10% +$173K ﹤0.01% 2437
2018
Q3 		$2.17M Sell
4,522
-237
-5% -$102K ﹤0.01% 2405
2018
Q2 		$2.16M Buy
4,759
+331
+7% +$210K ﹤0.01% 2353
2018
Q1 		$2.6M Buy
4,428
+130
+3% +$81K ﹤0.01% 2227
2017
Q4 		$2.67M Buy
4,298
+174
+4% +$125K ﹤0.01% 2204
2017
Q3 		$3.8M Buy
4,124
+256
+7% +$227K ﹤0.01% 2022
2017
Q2 		$3.61M Buy
3,868
+279
+8% +$274K ﹤0.01% 1981
2017
Q1 		$3.41M Buy
3,589
+186
+5% +$173K ﹤0.01% 1970
2016
Q4 		$2.73M Buy
3,403
+115
+3% +$104K ﹤0.01% 2042
2016
Q3 		$2.78M Buy
3,288
+166
+5% +$133K ﹤0.01% 1974
2016
Q2 		$2.57M Buy
3,122
+64
+2% +$69.7K ﹤0.01% 1940
2016
Q1 		$3.4M Buy
3,058
+196
+7% +$201K ﹤0.01% 1751
2015
Q4 		$3.57M Buy
2,862
+166
+6% +$275K ﹤0.01% 1735
2015
Q3 		$3.64M Sell
2,696
-64
-2% -$106K 0.01% 1681
2015
Q2 		$4.97M Buy
2,760
+366
+15% +$568K 0.01% 1547
2015
Q1 		$3.87M Sell
2,394
-31
-1% -$45.9K 0.01% 1684
2014
Q4 		$1.84M Sell
2,425
-440
-15% -$234K ﹤0.01% 2059
2014
Q3 		$1.14M Buy
2,865
+383
+15% +$185K ﹤0.01% 2244
2014
Q2 		$1.5M Buy
2,482
+738
+42% +$411K ﹤0.01% 2133
2014
Q1 		$1.2M Buy
1,744
+409
+31% +$274K ﹤0.01% 2195
2013
Q4 		$870K Buy
1,335
+223
+20% +$133K ﹤0.01% 2326
2013
Q3 		$701K Sell
1,112
-13
-1% -$5.86K ﹤0.01% 2396
2013
Q2 		$357K Buy
+1,125
New +$312K ﹤0.01% 2660

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Charles Schwab's TCRT Position: Q1 2024 in Review

Charles Schwab sold out of Alaunos Therapeutics (TCRT) in Q1 2024, closing a stake of 735 shares — an estimated $7.8K sold.

Charles Schwab first reported a position in TCRT in Q2 2013 and held it in 42 quarters. The position peaked at $5.29M in Q1 2021. 45 funds tracked by Wall St. Rank hold TCRT as of Q1 2024.

  • Charles Schwab reported no remaining Alaunos Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Charles Schwab sold 735 Alaunos Therapeutics shares in Q1 2024, an estimated $7.8K.
  • Charles Schwab first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 42 quarters.
  • Charles Schwab's Alaunos Therapeutics position peaked at $5.29M in Q1 2021.
  • 45 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2024.

Based on Charles Schwab's 13F filing for Q1 2024, filed 9 May 2024.